cyrilzakka/clinical-trials huggingface dataset:
Addition of Neostigmine to Levobupivacaine

Using the spermatic cord block has been of great advantage, as it has been cost saving, efficient technique whether used inon its own or combination with a sedative or . Furthermore, it provides minimal cardiac risks, early case ambulation, satisfactory postoperative pain control, as well as a reduced hospital stay and cost. one of the major drawbacks of spermatic cord block is being a single injection technique, leading to a short postoperative analgesia duration. So, to overcome this flaw some adjuvants were proven to prolong the analgesia duration as neostigmine.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged from 20 to 45 years.
* American Society of Anesthesiologists I-II.
* Undergoing Testicular Sperm Extraction Surgery.
* BMI from 18.5 to 40 kg/m2

Exclusion Criteria:

* Patient refusal
* Contraindications to regional anesthesia (bleeding disorders e.g. international normalized ratio \>1.5, Prothrombin Concentration \<70%, platelet count\<100 × 109, use of any anti-coagulants, local infection, etc.).
* Known allergy to local anesthetics.
* ASA III-IV.
* Patients aged less than 18 or more than 60.
* Body mass index \>35.:
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor hypoxia.


Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed head and neck squamous cell carcinoma
* Age \> 18 years old
* Patients must have unresectable disease in which there is no accepted potentially curative treatment option
* Patients must have acceptable organ and marrow function as defined below:
* leukocytes \>3,000/uL
* absolute neutrophil count \>1,500/uL
* platelets \>90,000/uL
* total bilirubin \<=1.5X normal institutional limits
* AST(SGOT)/ALT(SGPT) \<=2.5 X normal institutional limits with the following exceptions:

  1. Patients with documented tumors involving the liver who have Grade \<2 elevations in AST, ALT, and/or alkaline phosphatase are eligible if \<5X ULN.
  2. Patients with documented tumors involving bone who have a Grade \<2 elevation in alkaline phosphatase are eligible if \<5X ULN.
* creatinine \<=1.5X normal institutional limits OR creatinine clearance \>50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation
* Patients must have non-cranial gross disease that is greater than 1 cm on CT scan prior to enrollment
* Disease must be FDG-avid on PET scanning
* Creatinine within normal institutional limits
* Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix 1)
* Life expectancy \> 12 weeks
* Both men and women and members of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

* Women who are pregnant
* Administration of any systemic cytotoxic agents within the last 2 weeks of enrollment
* Patients who are unwilling or unable to provide informed consent
* Patients who have potentially curable disease
* Participation in another concurrent treatment protocol
ART Cycle Outcomes When Only 1 to 3 Oocytes Are Retrieved

This is a monocentric retrospective observational study. The study focuses on the women who underwent Assisted Reproductive Technology (ART) cycles with poor ovarian response (POR), defined as \<4 oocytes retrieved.

The objectives of the study are as follows:

* Evaluate clinical pregnancy rate (CPR) and cumulative live birth rate (CLBR) in women with poor ovarian response.
* Evaluate abortion rate in women with poor ovarian response.
* Evaluate the influence of patient characteristics (age, Anti-Müllerian hormone \[AMH\] levels, Antral Follicle Count \[AFC\], Follicle Stimulating Hormone \[FSH\], Body Mass Index \[BMI\]) on women with poor ovarian response.

To address the study objectives, data will be collected using a specific internal web-based database. All oocyte retrieval procedures performed at the Humanitas Fertility Center from January 2010 to December 2023 will be included in the evaluation. Outcomes will be expressed in terms of CLBR, CPR and Abortion Rate.


Eligibility Criteria:
Inclusion Criteria:

* The study database will include all women who underwent IVF treatment between 2010 and 2023 and were classified as poor ovarian responders, defined as those who retrieved fewer than 4 oocytes following controlled ovarian stimulation.

Exclusion Criteria:

* The study database will exclude women who underwent IVF treatment and retrieved more than 3 oocytes following controlled ovarian stimulation.
A Study on Nutrition Support Therapy of Patients With Liver Failure

This study is a Clinical trial to assess the efficacy of nutrition support therapy of patients with liver failure. Patients were randomized to one of 2 groups to receive different nutrition and energy support treatment.

Patients with liver failure (defined by APASL) induced by any precipitating factors were randomized to two groups; a treatment group and a control group. Participants in treatment group were provided with a standard hospital diet that provided 25-30 kcal/kg/day . Patients in control group receive diet guide

Eligibility Criteria:
Inclusion Criteria:

1. Male and female patients from 18 to 65 years of age;
2. Patient inclusion criteria: jaundice (serum total bilirubin ≥5 mg/dl) and coagulopathy (INR ≥ 1.5 or prothrombin activity ≥ 40 %), accompanied by ascites and/or encephalopathy within 4 weeks.

Exclusion Criteria:

1. Surgery with in 4 weeks
2. three degree hepatoencephalopathy
3. malignant tumors
4. cardiac failure or respiratory failure
5. liver transplantation within observing period -
Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1)

To evaluate the feasibility, acceptability and effectiveness of Multiple Channel Exposure Therapy-Veterans (MCET-V) as a treatment for returning service members with comorbid posttraumatic stress disorder (PTSD) and panic disorder (PD) in two phases. The first phase of the study will examine the feasibility and acceptability of MCET-V.

With the increasing number of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) veterans returning from war-zone areas, many will experience anxiety disorders such as PTSD and comorbid problems. Currently, about one in every six OIF/OEF veterans experiences PTSD and co-occurring PD. Although effective treatments exist for treating one or the other, we do not yet have treatments that can simultaneously target PTSD and PD. Thus, recent attention has focused on the development of multi-component treatments that simultaneously address PTSD and PD. This study is the first systematic investigation of a time-limited, multi-component cognitive-behavioral treatment for veterans with specific comorbid anxiety problems. The purpose of the first phase of the study is to evaluate the feasibility and acceptability of the multi-component cognitive-behavioral treatment in an open trial.

Eligibility Criteria:
Inclusion Criteria:

* being a veteran of any era;
* being enrolled in the Trauma Recovery Program (TRP) at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), with a current diagnosis of PTSD and PD;
* being stable on psychotropic medication for 4 weeks before study participation; and
* being at least 18 years of age.

Exclusion Criteria:

* active substance dependence, or bipolar or psychotic disorders;
* severe depression and active suicidal ideation and intent (based on Structured Clinical Interview for DSM-IV disorders \[SCID-IV\] \& Beck Depression Inventory-2nd edition \[BDI-II\]);
* cognitive impairment as indicated by the St. Louis University Mental Status exam (SLUMS); and
* veterans currently receiving psychosocial treatment specifically targeting PTSD or panic symptoms.
A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers

A randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of Dilatrend SR 64mg capsule after oral administration in healthy male volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Between 20 aged and 50 aged in healthy adults
* Weight more than 55kg, IBW 20% within the range
* Agreement with written informed consent

Exclusion Criteria:

* Subject has hypersensitivity reaction or clinically significant history about investigational drug
* Clinically significant cardiovascular system, respiratory system, liver, renal, endocrine system, gastrointestinal system, central nervous system, blood tumor, mental disease, skin disease and so on
* Inadequate result of laboratory test

  * AST(SGOT) or ALT(SGPT) \> 1.5 x upper limit of normal range
* Continued to be taking caffeine (caffeine \> 5 cup/day), drinking(alcohol \> 210 g/day) or during clinical trials can not be drunk or severe heavy smoker (cigarette \> 10 cigarettes per day)
* Creatinine clearance \< 80ml/min
* Subject with known for history(such as gastrointestinal disease or operation) with affect the absorption of drug
* Subject takes an abnormal meal which affect the ADME of drug
* Previously participated in other trial within 90 days
* Previously make whole blood donation within 60 days or component blood donation within 30 days
* Subject with positive reaction for reason of laboratory test result
* An impossible one who participates in clinical trial by investigator's decision including for reason of laboratory test result
Evaluation of the Colonization Capacity of a Probiotic Bacterium.

The goal of this interventional study is to test the colonization of a new generation probiotic in normal weight and overweight/obese people.

The main question aims to answer is if our bacteria is able to colonize the human intestine.

Participants will recieve a probiotic pill every day during 15 consecutive days and fill in questionaries.

Normal weight and overweight volunteers will be recruited to evaluate the colonization capacity of the bacteria. In this case, stool samples will be taken before starting the intervention (T0), after the treatment (T1) and a week after fiinishing the administration of the probiotic (T2). All the subjects will receive the probiotic supplement in capsules taken daily, 7-8 normal weight subjects will take a concentration of 10\^9-10 CFU and 7-8 overweight subjects will take a concentration of 10\^9-10 CFU.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 65 years.
* Body mass index between 20-25 kg/m2 for normopese subjects and BMI 25-30 kg/m2 for overweight participants.
* Body weight and eating habits stable in the last three months before the first visit.
* Willingness to participate in the intervention study, giving their data and samples.
* Signature and acceptance of the informed consent.

Exclusion Criteria:

* Preexistence of other physical conditions (food allergy/sensitivity, gastrointestinal conditions \[such as inflammatory bowel disease, celiac disease, pancreatitis, chronic constipation, etc.\], immunodeficiency)
* Eating disorders
* Use of antibiotics one month prior to the first visit
* Chronic use of medications (antacids, antidiabetics, anti-hypertensives, etc.)
* History or current abuse of drugs or alcohol
* Following a vegetarian, vegan, or other restrictive diet
* Any other reason deemed appropriate for exclusion at the clinician's discretion
* Non-compliance with adherence to treatment regimen
* Direct association with research and/or investigators
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.

Rationale: Seizures emerge as a complication of hypoxic-ischemic brain injury in near a third of patients successfully resuscitated from cardiac arrest. Seizures post-cardiac arrest can be refractory to treatment with anti-seizure medications and anesthetics may be used for refractory status epilepticus control. Anesthetic treatment guided by continuous EEG can target burst suppression or seizure suppression, however it is not known which strategy is superior for achieving PCARSE control.

Objective: determine the safety and feasibility of post-cardiac arrest refractory status epilepticus (PCARSE) treatment using EEG goals for intravenous anesthetic titration (burst suppression vs. seizure suppression).

Clinical Trial Phase: II

Study Design: prospective, randomized, open-label, blinded end-point, concurrently-controlled, parallel arms design clinical trial.

Study Period: two years

Study Population: unconscious cardiac arrest survivors with return of spontaneous circulation who develop post-cardiac arrest refractory status epilepticus (PCARSE).

Interventions: anesthetic use targeting burst suppression vs. seizure suppression on EEG for 24 hours. Intervention maybe repeated using the dame EEG target once in case of PCARSE recurrence.

Sample Size: 30 subjects randomized in a 1:1 ratio to either burst suppression or seizure suppression EEG targets.

Primary Endpoints: Safety and feasibility of seizure control using burst suppression or seizure suppression EEG targets for PCARSE treatment.

Secondary Endpoints: Seizure recurrence incidence, time to seizure recurrence, number and dose of anti-seizure medication and anesthetic needed for PCARSE control, Death or disability according to the Cerebral Performance Category at Discharge (30 days), and Death or disability according to the modified Rankin Scale at Discharge (30 days).

Risks: Participants receiving anesthetics for PCARSE treatment will be monitored for hypotension, propofol infusion syndrome, and hypertriglyceridemia. Patients with PCARSE are at high risk for death and prolonged hospital stays.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years old
2. Non-traumatic, out-of-hospital cardiac arrest
3. Comatose on admission - defined as not following commands
4. Return of spontaneous circulation (ROSC) within less than 45 minutes
5. Admission to the intensive care unit
6. Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous

EEG monitoring within 7 days from ROSC

Exclusion Criteria:

1. Acute cerebral hemorrhage or infarction
2. Pregnancy
3. Prisoners
Usefulness of High Resolution Manometry in Constipation

Constipation is a frequent symptom that is reported by more than 10% of the general population. In a few case, constipation is resistant to medical standard care, including osmotic and stimulant laxatives. The diagnosis of colonic inertia may be suspected in these patients although diagnostic criteria for colonic inertia may vary from one country to another. In France, the diagnosis of colonic inertia is based on manometric study of the colorectal contractile activity using manometric probe. Using conventional manometric catheters, severe alteration of the colorectal motility is found in a very small subset of patients, who may later benefit from surgery. The recent use of high resolution manometric probe allowed to map more precisely colorectal motility, but whether these new parameters are relevant remains to be assessed. The aim of this study is to assess the diagnostic performance of a new high resolution manometric probe by comparing healthy volunteers to patients suspected of colonic inertia.


Eligibility Criteria:
For patient

Inclusion Criteria:

* Age between 18 and 65 years
* chronic Constipation (\> 6 months)
* delayed colonic transit time \> 100 h
* normal colonoscopy
* constipation refractory to at least 1 osmotic and 1 stimulant laxative according French guidelines on constipation ;
* Affiliated to French national healthcare insurance

Exclusion Criteria:

* Patient with constipation being either:

  * With colonic transit time \<100h
  * Distal (with radio-opaque markers stasis in the rectum)
  * From organic origin
  * Recent (\<6 mois)
  * Relieved using osmotic or stimulant laxatives
* Contra-indication to the use of high resolution manometry insertion

  * Intestinal occlusion
  * Coagulation disorders, including anti-coagulant treatments
  * General anesthesia contra-indication
  * colonoscopy contra-indication
* failure to perform a colonoscopy in previous attempts
* medication intake that may impair colorectal motility, including opioids
* Evolutive inflammatory of neoplasia process
* History of major digestive surgery (at exclusion of appendicectomy, cholecystectomy)
* Presence of condition that may impact digestive motility, including diabetes mellitus and sclerodermia
* Cardiologic disease that may represent a contraindication to vagal stimulation

For Healthy volunteers

Inclusion Criteria:

* Age between 18 and 65 years
* Affiliated to French national healthcare insurance

Exclusion Criteria:

* Significant digestive evolutive disease
* constipation with Kess score \> 11/39 and colonic transit time ≥ 60 h
* Contra-indication to the use of high resolution manometry insertion

  * Intestinal occlusion
  * Cardiac disease
  * Coagulation disorders, including anti-coagulant treatments
  * General anesthesia contra-indication
  * colonoscopy contra-indication
* History of major digestive surgery (at exclusion of appendicectomy, cholecystectomy)
* Presence of condition that may impact digestive motility, including diabetes mellitus and sclerodermia
Injection of Autologous Adipose Tissue for Treatment of Osteoarthritis in the Knee

Evaluating the safety and efficacy of a single injection of autologous adipose tissue for treatment of osteoarthritis of the knee.

This clinical trial is a single site, double blinded, paired within groups, controlled clinical study to investigate the safety and efficacy in the use of adult autologous adipose tissue for the treatment of pain associated with joint OA. The hypothesis of this trial is that the treatment will be safe and the proposed clinical outcome measures of reduced pain resulting from the treatment of OA of the knee joint with autologous adipose tissue will be superior to a placebo control treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Bilateral K-L Grade II through Grade IV osteoarthritis as diagnosed by physician review of weight bearing X-ray or MRI excluding subjects whose knee pain is caused by, (i) diffuse edema, (ii) displaced meniscus tear, (iii) lesion greater than 1 cm in any direction, or (iv) osteochondritis dissecans.
2. Study Participants must be willing to voluntarily give written Informed Consent to participate in the study and sign the Health Insurance Portability and Accountability Act (HIPAA) authorization before any study procedures are performed.
3. Males and females 40-75 years old.
4. Participants will be in good health (ASA Class I-II) with a BMI \< 35.
5. Continued pain in the knee despite conservative therapies for at least 6 months.
6. Participants must present with a bilateral knee pain scores ≥6 and ≤16 using the short-form WOMAC pain (A1 subscale, 20 total points).
7. Must speak, read and understand English.
8. Subjects must be reasonably able to return for multiple follow-up visits.

Exclusion Criteria:

1. Participants who have had surgery of either knee within 6 months prior to the screening visit.
2. Participants who have had a major injury to either knee within 12 months prior to enrolling in the study.
3. Participants who have had an injection in either knee in the prior 6 months, including corticosteroids, viscosupplementation or platelet rich plasma (PRP).
4. Participants who have gout, rheumatoid arthritis, lupus arthropathy, psoriatic arthritis, avascular necrosis, severe bone deformity, infection of the knee joint, fibromyalgia, pes anserine bursitis, or neurogenic or vascular claudication.
5. Participants who have symptomatic OA of the hips, spine, or ankle that would interfere with the evaluation of the treated knee.
6. Participants that are unwilling to stop taking prescription pain medication 7 days prior to any visit.
7. Participants that are allergic to lidocaine, epinephrine or valium
8. History of bleeding disorders, anticoagulation therapy that cannot be stopped 3 days prior to injection
9. Subjects that use any form of tobacco to include e-cigarettes more than once a week within the last 6 months
High Dose Chemotherapy Followed By PBSC Rescue for HD

To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.

Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Eligibility Criteria:
Inclusion Criteria:- adequate organ function

* recurrent HD Exclusion Criteria:- CNS disease
* no prior malignancy
Reeducation of Chronic Achilles Tendinopathy by Wearing Shoes Inclined Versus Reeducation by Kinesitherapy

The purpose of the study is to compare the treatment by wearing shoes inclined at kinesitherapy because it is the first treatment offered by primary care physicians in chronic Achilles tendinopathy.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18-75 years
* Disease: chronic Achilles tendinopathy de novo or recurrent confirmed by ultrasound
* Patients having signed the informed consent for the study participation
* Patients covered by medical insurance
* Patients having no behavioral disorders

Exclusion Criteria:

* History of rupture of the Achilles tendon (= stage 4)
* Antibiotic treatment tendinotoxique (Quinolones, ...)
* Inability to walk more than 30 minutes per day.
* Haglund Syndrome
* Treatment of tendinopathy or being older than six months
* Minors
* Major trust
Danazol Treatment in Endometriosis Women Before IVF

The purpose of this study is to determine whether pre-treatment with danazol for at least 4 months before controlled ovarian hyperstimulation for IVF cycles improves pregnancy rate.

Endometriosis is a chronic benign disease defined by the presence of endometrial tissue outside the uterine cavity, affecting women in their reproductive age. This disease is clinically characterized by infertility pelvic pain and the presence of ovarian cysts, endometriomas, and affects the about 10% of women. Women with endometriosis when undergo IVF show lower pregnancy rate than general population, and a reduced ovarian reserve, due to the diseases and often to ovarian surgery. The aim of this study is to evaluate if a pre-treatment with danazol, an anti-estrogenic agent, may improve the otcome of IVF cycles in these women

Eligibility Criteria:
Inclusion Criteria:

- Clinical diagnosis of endometriosis previous laparoscopic surgery for ovarian endometriotic cysts infertility

Exclusion Criteria:

- age more than 40 years systemic disease antimulleran hormone (AMH)\<1 and FSH\>20
The Effect of Household Air Pollution on Lung Function Growth in Infants With Pneumonia in Sub-Saharan Africa

This study will evaluate the feasibility and acceptability of a household-based clean air intervention

A clean air intervention will be implemented in each household, including HEPA- based air filtration, solar lighting, and education. The air filtration system will be cycled monthly, with active filtration alternating with no filtration for one month on/one month off. To determine the effect of the clean air intervention within the household, PM2.5 concentration during each cycle and lung function will be measured among household members.

Eligibility Criteria:
Inclusion Criteria:

* Age \< 12 months

  • First episode of WHO-defined severe pneumonia22: cough or difficulty breathing with
* Oxygen saturation \< 90% or central cyanosis,
* Severe respiratory distress, or
* Signs of pneumonia with a general danger sign
* Be willing to commit to entire 2 years of follow up visits.
* (Controls) Matched to each case on age (+/-1 month), sex, and community

Exclusion Criteria:

* Craniofacial, cardiac or other major malformation
* Neuromuscular condition that affects respiration
* Outside Smart Discharges Project catchment area
* Prior hospitalizations or known episodes of respiratory illness or episodes of pneumonia before index admission,